Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an exclusive option and license ...

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Trafficking and exploitation can be a blind spot for business leaders, putting employees at risk and exposing the ...

Kymera Therapeutics, Inc. has announced an update to its partnership with Sanofi regarding the advancement of a ...

Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc.

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

Wells Fargo cut the price target for The Trade Desk, Inc. TTD from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded ...